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Increased susceptibility to tuberculosis following HIV-1 seroconversion contributes sig-
nificantly to the tuberculosis epidemic in sub-Saharan Africa. Lung-specific mechanisms
underlying the interaction between HIV-1 and Mycobacterium tuberculosis infection are
incompletely understood. Here we address these questions by examining the effect of
HIV-1 and latent M. tuberculosis co-infection on the expression of viral-entry receptors
and ligands in bronchoalveolar lavage (BAL) of HIV-1-infected and -uninfected patients
with and without latentM. tuberculosis infection. Irrespective of HIV-1 status, T cells from
BAL expressed higher levels of the beta-chemokine receptor (CCR)5 than peripheral blood
T cells, in particular the CD8+ T cells of HIV-1-infected persons showed elevated CCR5
expression. The concentrations of the CCR5 ligands RANTES and MIP-1β were elevated
in the BAL of HIV-1-infected persons compared with that in HIV-1-uninfected controls.
CCR5 expression and RANTES concentration correlated strongly with HIV-1 viral load
in the BAL. In contrast, these alterations were not associated with M. tuberculosis sen-
sitisation in vivo, nor did M. tuberculosis infection of BAL cells ex vivo change RANTES
expression. These data suggest ongoing HIV-1 replication predominantly drives local
pulmonary CCR5+ T-cell activation in HIV/latent M. tuberculosis co-infection.
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Introduction
Tuberculosis and AIDS are amongst the leading causes of death
worldwide. In the majority of cases in immunocompetent per-
sons, Mycobacterium tuberculosis is successfully controlled by
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local immune responses leading to isolation of infected alveolar
macrophages and the formation of granulomas. In HIV-1 infec-
tion, the rate of active tuberculosis following primary infection and
the rate of reactivation of tuberculosis in individuals with latent
M. tuberculosis infection is greatly increased although the under-
lying mechanisms are not well understood [1].
T-cell mediated immunity is critical for immune control of
tuberculosis. HIV-1 replicates in activated CD4+ T cells, monocytes
or dendritic cells and leads to immunodeficiency characterised by
progressive CD4+ T-cell depletion. Moreover, despite relatively
normal numbers of circulating CD4+ T cells HIV-1-infected per-
sons are already at increased risk of tuberculosis in the first year
following seroconversion [2]. HIV-1 infection impairs not only the
quantity but also the quality of M. tuberculosis-specific immune
responses [3]. In addition mortality remains higher after success-
ful anti-tuberculosis treatment of HIV-1-infected persons [4], even
though CD4+ T-cell numbers partially reconstitute after initiation
of anti-retroviral therapy (ART) [5].
T-cell activation is an important mechanism of HIV-1 patho-
genesis [6] and persistent cell expression of activation markers
predicts the progression into AIDS [7]. So far only a few studies
have investigated the activation markers CD38, CD69 and Ki67
on BAL cells at the site of active tuberculosis disease [6, 8, 9].
Chronic antigen exposure in latent M. tuberculosis infection may
lead to a persistent localised immune activation that facilitates
HIV-1 entry into CD4+ T cells in lungs. The alpha (CXCR)4 and
beta chemokine receptors (CCR)5 are the most important corecep-
tors for HIV-1 entry and infection of CD4+ T cells [10,11]. CCR5
expression on CD8+ T cells mediates the migration of antigen-
specific effector and differentiated memory CD8+ T cells to the
site of inflammation and it has been suggested that these CD8+
T cells are important in eradication of virus-infected CD4+ T cells.
The ß-chemokines MIP1α, MIP1β and RANTES attract CCR5+
T cells to the region [12].
To evaluate the hypothesis that HIV-1 infection or M. tuber-
culosis exposure influence CCR5 and CXCR4 receptor and ago-
nist expression, receptor expression and chemokine profiles from
the peripheral blood and BAL mononuclear cells were compared
between in HIV-1-infected and -uninfected persons with and with-
out evidence of M. tuberculosis sensitisation.
Results
Participants
Blood and BAL cells from age- and sex-matched groups of 15
HIV-1-infected and 21 HIV-1-uninfected persons from an area
of high tuberculosis incidence and high HIV-1 prevalence were
investigated [3] (Table 1). Ten HIV-1-infected and 11 HIV-1-
uninfected participants were diagnosed with latent M. tubercu-
losis infection by a positive ESAT-6 and/or CFP-10 specific IFN-γ
immune response in an ELISPOT assay performed with PBMCs in
the absence of active tuberculosis disease. HIV-1-infected persons
had a median CD4+ count of 226 cells/μL. Frequencies of CD4+
CD3+ T cells were significantly lower in blood (median 10.0 ver-
sus 42.4%, p < 0.001) and BAL lymphocytes (median 7.7 versus
37.7%, p < 0.001) when compared with those in HIV-1-uninfected
persons (Table 1).
HIV-1 viral load
Stratification of BAL urea level by HIV-1 status revealed no differ-
ence between HIV-1-uninfected and -infected people (p = 0.64,
data not shown). To compare the tissue load of HIV-1 in the lungs
with the levels in blood, the viral load was determined in serum
and BAL (Fig. 1A). In 5 out of 15 HIV-1-infected persons the viral
load in BAL was below the detection limit (individuals marked
in the graphs). The median viral load in serum was 22 000 RNA
copies/mL (range 590–660 000 copies/mL). A significantly lower
median of 1964 RNA copies/mL (range 855–709 088 copies/mL)
was found in BAL (p = 0.030). Nevertheless, in three cases the
viral load in the BAL was higher than the viral load in serum. There
was a positive correlation between the viral load in serum and in
lungs (ρ = 0.787, p < 0.001, Fig. 1B). Figure 1C demonstrates an
inverse correlation (ρ = −0.586, p = 0.022) between viral load
and the proportion of CD4+ in BAL.
HIV-1 receptor expression on bronchoalveolar T cells
Several mechanisms of increased HIV-1 replication have been
described at the site of M. tuberculosis infection [13]. In the
previous study [3] which was performed with the same partic-
ipants, no differences were found in the T-cell memory pheno-
type between HIV-1-infected and -uninfected persons, but in both
groups there was a shift to the predominance of CD4+ effector
T cells in BAL when compared with blood. As these activated effec-
tor T cells in the lungs may facilitate HIV-1 entry, BAL mononu-
clear cells (BALMCs) were characterised for their expression of
the HIV-1 entry receptors CCR5 and CXCR4. Comparing the com-
partments, CD4+ (Fig. 2A) and CD8+ BALMCs (Fig. 2B) invari-
ably had significantly higher expression of the CCR5 receptor
than Peripheral blood mononuclear cells (PBMCs) (p < 0.001),
measured by median fluorescence intensity (MFI). No differences
in CCR5 expression by CD4+ blood T cells were found between
HIV-1-infected and -uninfected persons, whereas CCR5 expres-
sion by CD4+ T cells in BAL was slightly higher in HIV-1-infected
persons than in HIV-1-uninfected participants (178 versus 153)
although the difference was not significant (p = 0.37, Fig. 2A).
Similarly, CCR5 expression by peripheral CD8+ T cells did not dif-
fer between HIV-1-infected and -uninfected persons. In contrast,
CCR5+ expression by CD8+ T cells in BAL was moderately higher
in HIV-1-infected persons (222.5 versus 116.5, p= 0.026, Fig. 2B).
Levels of CCR5 on CD4+ and CD8+ BAL T cells were directly cor-
related with viral load in BAL (ρ = 0.706, p = 0.005, Fig. 2C and
ρ = 0.793, p < 0.001, Fig. 2D). In contrast, stratifying CCR5
expression on CD4+ and CD8+ BALMCs by M. tuberculosis infec-
tion status did not reveal any difference (data not shown).
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Table 1. Characteristics of persons enrolled to the study
HIV-1 infected HIV-1 uninfected p-value
N 15 21
Sex: female/male, n 11/4 13/8 0.564
Age, mean years (range) 34.3 (24–51) 32.7 (21–55) 0.531
CD4, median CD4 cells/μL (range) 226 (61–595) 786 (461–1225) <0.001a)
Blood CD4+, median CD4+ as % of CD3+ T cells (range) 10.0 (3.45–28.9) 42.4 (9.46–67.8) <0.001a)
BAL CD4+, median CD4+ as % of CD3+ T cells (range) 7.7 (1.33–31.30) 37.7 (12.5–78.7) <0.001a)
Blood viral load, median RNA copies/mL, (range) 22 000 (590–660 000)
BAL viral load, median RNA copies/mL, (range) 1964 (855–709 088)
Response to ESAT-6/CFP-10, blood: positive/negative 10/5 11/10 0.190b)
a)Differences between the HIV-1-infected and -uninfected groups were compared using the Mann–Whitney U-test.
b)Difference of ESAT-6/CFP-10-induced IFNγ-response in PBMCs between HIV-1-infected and -uninfected groups was compared using Fisher’s
exact test of probability.
The pattern of CXCR4 expression on T cells differed from CCR5
expression. Levels of CXCR4 expression on CD4+ T cells trended to
be higher on BALMCs than on PBMCs in HIV-1-uninfected subjects
(201.5 versus 124.5, p = 0.049), whereas no difference in CXCR4
expression was observed between BAL or blood CD4+ T cells
of HIV-1-infected persons. CXCR4 expression on CD4+ BALMCs
was significantly higher in the HIV-1-uninfected control group
when compared with that of HIV-1-infected persons (201.5 versus
114.5, p = 0.009, Fig. 2E). No correlation was found between
CXCR4 expression by CD4+ BALMCs and viral load in BAL in
HIV-1-infected persons (data not shown).
CXCR4+ expression on CD8+ PBMCs did not differ by HIV-1
status. BALMCs CD8+ T cells expressed higher levels of CXCR4+
than PBMCs in HIV-1-infected persons (159.5 versus 83.9, respec-
tively, p = 0.003, Fig. 2F), whereas the slightly higher CXCR4
expression on CD8+ BAL T cells compared with that of PBMCs in
the HIV-1-uninfected group was not significant (193 versus 129.5,
p = 0.059).
Level of CCR5 ligands
Blockade of the CCR5 receptor by drugs, such as Maraviroc, can
prevent the entry of CCR5-tropic HIV-1 into target cells [14, 15].
As differences were observed in the expression of CCR5 in BAL
compared with that in blood, CCR5 ligand levels were ascertained
in the two compartments by measuring the transcript levels of the
three CCR5 agonists RANTES, MIP-1β and MIP-1α in BALMCs.
A lower threshold cycle (CT) represents a higher abundance
(Fig. 3). RANTES abundance was significantly higher in HIV-1-
infected than in uninfected participants (median CT 2.68 versus
7.27, p = 0.003). The mean abundance of MIP-1β was slightly
but not significantly higher in HIV-1-infected (median CT 5.70),
when compared with that of HIV-1-uninfected persons (median
CT 7.02, p = 0.225), whereas MIP-1α transcript abundance in
BAL was comparable in HIV-1-infected and uninfected persons.
Having observed differences in transcript abundance, the pro-
tein levels of RANTES, MIP-1β and MIP-1α were investigated by
multiplex bead array in blood and BAL. RANTESwas found at high
concentrations in serum, but at significantly lower concentrations
in the BAL (p < 0.001). The level of this chemokine in serum was
independent of HIV-1 status, whereas significantly higher RANTES
levels were recorded in the BAL of HIV-1-infected versus HIV-1-
uninfected persons (2725 pg/mL versus 594.6 pg/mL, p < 0.001,
Fig. 4A). The RANTES levels in BAL also correlated with viral load
in the same compartment (ρ = 0.635, p = 0.011, Fig. 4D), whereas
elevated RANTES levels were not associated with M. tuberculosis
sensitisation status (data not shown).
MIP-1β levels in blood were comparable in HIV-1-uninfected
and -infected persons. In contrast, MIP-1β was elevated in the
BAL of HIV-1-infected compared with that of HIV-1-uninfected
persons (497.2 pg/mL versus 194.3 pg/mL, p = 0.004). Further-
more, MIP-1β levels in the BAL of HIV-1-infected participants were
significantly higher when compared with that of the blood com-
partment (497.2 pg/mL versus 202.8 pg/mL, p < 0.001, Fig. 4B).
Only low concentrations of MIP-1αwere detected in both blood
and serum. The serum levels of MIP-1α in HIV-1-infected partici-
pants did not differ from uninfected persons. The MIP-1α level in
the BAL tended to be slightly higher in HIV-1-infected versus unin-
fected persons (73.7 pg/mL versus 44.7 pg/mL, p = 0.113). Com-
paring both, blood and BAL compartments, significantly higher
levels of MIP-1α were found in the BAL compared with that in the
serum of HIV-1-infected (73.7 pg/mL versus 15.2 pg/mL, respec-
tively, p < 0.001) and HIV-1-uninfected participants (44.7 pg/mL
versus 23.5 pg/mL, p = 0.01, Fig. 4C).
No difference in the concentration of CXCR4 ligand stromal
cell-derived factor 1 (SDF-1α) in serum was observed between
HIV-1-infected and -uninfected persons. Levels of SDF-1α in BAL
samples were all below the detection limit of 18.9 pg/mL (data
not shown).
Effect of M. tuberculosis infection on CCR5 ligand
expression
To investigate if differences in CCR5 ligand expression were due
to HIV-1 infection or M. tuberculosis, BALMCs were cultured
in the presence or absence of M. tuberculosis H37Rv for 24 h
and transcript abundance measured by RT-PCR. Incubation
with H37Rv decreased RANTES expression in BALMCs from
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Figure 1. Viral load (VL) in bronchoalveolar lavage (BAL). (A) Paired VL
in serum (n = 15, open triangles) and BAL fluid (n = 15) was measured
by nucleic acid amplification tests of gag for the quantitation of human
HIV-1 RNA. The detection limit was 20 copies/800 μL of pure BAL fluid.
BAL VLs above the detection limit are depicted with open circles (n =
10). BAL VL values lower the detection limit (LDL) were set to a value
of 19 copies/mL and normalised according to the urea method (n = 5,
symbol ×). Each symbol represents an individual sample, horizontal
lines represent median VL of serum and BAL. *p = 0.030 between serum
and BAL VL, Wilcoxon signed rank test. (B) Correlation between VL in
serum and BAL was assessed by Pearson (ρ = 0.787, p < 0.001) and
(C) correlation between VL BAL and the relative frequency of CD4+
CD3+ BAL T cells was assessed by Spearman (ρ = −0.586, p = 0.022).
Data shown are pooled data from 15 experiments performed.
HIV-1-infected persons (median 0.84-fold induction), BALMCs of
HIV-1-uninfected persons showed a slight increase in RANTES
expression (median 1.20-fold, p = 0.034, the difference is within
experimental error). H37Rv induced little increase in MIP-1β
(medians 1.28-fold in HIV-1-infected in comparison to 1.89-fold
in HIV-1-uninfected). Similarly, median fold increases of 1.31
and 1.69 were observed in MIP-1α transcripts in HIV-1-infected
and -uninfected persons, respectively. Therefore the influence of
M. tuberculosis on the gene expression level of CCR5 agonists
was not great, with RANTES gene expression even diminished in
HIV-1-infected persons (Fig. 5).
Discussion
The immunological mechanisms underlying the increased risk of
tuberculosis in persons with HIV-1 co-infection, and those that
exazerbate in the course of both diseases, are unclear. The aim
of this study was to investigate the influence of HIV-1 infection
on immune activation of resident bronchopulmonary lymphocytes
and a possible permissive environment for HIV-1 entry and repli-
cation. Therefore, chemokine receptors and chemokine profiles of
the two compartments lavage and blood of HIV-1-infected and
-uninfected persons from an area of high tuberculosis exposure
were compared. The key findings of this study are: (i) viral load
correlates inversely with the number of CD4+ T cells in BAL,
(ii) CD8+ BAL T cells of HIV-1-infected persons express higher
levels of CCR5 compared with HIV-1-uninfected persons, and
(iii) the observed elevation of MIP-1β and RANTES levels in BAL
of HIV-1-infected persons was not further upregulated by ex vivo
M. tuberculosis infection.
In this study HIV-1 viral load in BAL correlated directly
with viral load in serum and inversely with CD4+ cell count in
BAL. These data support previous observations of HIV-1 repli-
cation in lungs [16, 17]. Previous studies have demonstrated
that HIV-1 replicates in alveolar macrophages [18, 19], others
showed that CCR5+ CD4+ BAL T cells support replication [5,20].
These results show in some people an elevation of HIV-1 RNA
concentration in BAL fluid compared to serum, which supports
compartmentalised local viral replication in human lungs. Fur-
thermore, lung segments affected by tuberculosis disease have
significantly higher HIV-1 viral load than uninvolved paired lung
segment [21]. This may be partially explained by the finding that
activated T cells display greater permissiveness to infection and
viral replication, compared with quiescent cells [22]. To this end,
HIV-1 replication was recently associated with M. tuberculosis-
specific CD4+ T cells, compared with CMV-specific CD4+
T cells [23].
This study compared expression of the HIV-1 entry receptors
on BAL and blood T cells of HIV-1-infected and -uninfected per-
sons living in an area of high tuberculosis incidence. There was
a wide range of CXCR4 expression levels on T cells, with sig-
nificantly decreased levels of CXCR4+ on CD4+ BAL T cells of
HIV-1-infected compared with those of HIV-1-uninfected persons.
However, CXCR4 expression by CD4+ BALMCs was not associ-
ated with HIV-1 viral load in the same compartment, confirming
previous findings [24].
Higher levels of CCR5 expression were observed on CD4+ BAL
T cells by comparison with peripheral blood cells. This may be
due to the fact that CCR5 is mainly expressed on effector memory
(CD45RA− and CD27−) T cell [25], the predominant T-cell subset
in BAL [3]. As CCR5 expression increases permissiveness to HIV-1
infection [11], the elevated expression of CCR5 on CD4+ BAL
C© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
544 Barbara Kalsdorf et al. Eur. J. Immunol. 2013. 43: 540–549
Figure 2. CCR5 and CXCR4 expression on CD4+ or CD8+ T cells in blood and BAL. (A, B, E, F) The median fluorescence intensity (MFI) of (A, B) CCR5
and (E, F) CXCR4 receptor expression wasmeasured by flow cytometry on (A, E) CD4+ and (B, F) CD8+ cells from the blood and BAL of HIV-1-infected
(n = 12 in blood, n = 14 in BAL, open squares) and HIV-1-uninfected persons (n = 16 in blood, n = 14 in BAL, solid circles), each sign represents
one individual, bars represent medians. Differences between CCR5 expression on CD4+ and CD8+ T cells from paired blood and BAL samples were
calculated by Wilcoxon signed rank test (***p < 0.001). The CCR5 expression on CD8+ T cells in the BAL was significantly higher in HIV-1-infected
compared to HIV-1-uninfected persons (*p = 0.026, by Mann–Whitney U-test). (C, D) The correlation between viral load (VL) in BAL and MFI of
(C) CCR5+ on CD4+ (ρ = 0.706, p = 0.005) or (D) CD8+ (ρ = 0.793, p < 0.001) BAL T cells of HIV-1-infected participants was assessed by Spearman.
Open circles, BAL VL; symbol ×, BAL VL LDL were set to a value of 19 copies/mL and normalised according to the urea method. (E) The difference
of CXCR4 expression on CD4+ paired blood and BAL T cells was measured by Wilcoxon signed rank test (*p = 0.049). MFI of CXCR4+ CD4+ BALMCs
was significantly higher in the HIV-1-uninfected control group when compared with that of HIV-1-infected persons (**p = 0.009, Mann–Whitney
U-test). (F) BAL CD8+ T cells expressed higher levels of CXCR4 than PBMCs in HIV-1-infected persons (**p = 0.003), differences between the HIV-1
status were assessed by Mann–Whitney U-test. Data shown are pooled data from experiments on 12 blood and 14 BAL samples of HIV-1-infected
and 16 blood and 14 BAL samples of HIV-1-uninfected persons.
T cells might increase BALMC susceptibility to HIV-1 infec-
tion. Our finding that HIV-1 viral load correlated with CCR5
expression on CD4+ BAL T cells supports this hypothesis.
Therefore these data add to previous descriptions of BALMCs
expression of CCR5 [5, 9, 20, 26] at the site of M. tuberculosis
infection.
Findings from this study suggest that HIV-1 infection induces
the elevation of CCR5+ expression on CD8+ BAL T cells. Although
increased expression of CCR5 on CD8+ T cells is not directly
related to HIV-1 susceptibility, CD8+ T cells play a critical role
in the control of viral infection. During HIV-1 infection cyto-
toxic T-lympocytes eliminate HIV-1-infected cells and secrete
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Figure 3. Constitutive transcript abundance of CCR5 ligands in BAL
cells. Constitutive transcript abundance was assessed in freshly iso-
lated BALMCs of HIV-1-infected persons (n = 12, open squares) and
HIV-1-uninfected persons (n = 10, solid circles). CT = (CT gene
of interest) − (CT β-actin). A lower CT indicates higher transcript
abundance. Each symbol represents one sample, bars represent medi-
ans. Differences between constitutive RANTES transcript abundance of
HIV-1-infected and -uninfected persons was determined by the Mann–
Whitney U-test (**p = 0.003). Data shown are pooled data from experi-
ments on 12 HIV-1-infected and 10 HIV-1-uninfected persons.
β-chemokines [27], which recruit monocytes and T cells to inflam-
matory sites. Because our results showed an increased presence of
CD8+ T cells at the site of infection, we expected to find an ele-
vation of the β-chemokines RANTES, MIP-1β and MIP-1α in BAL.
This hypothesis was confirmed as higher levels of RANTES and
MIP-1β were found in the BAL of HIV-1-infected in comparison to
HIV-1-uninfected persons. It should be noted that soluble
chemokines can be used to determine relative changes of these
peptides during an inflammatory process but may more represent
evidence of inflammation than a biological relevant form of these
mediators. Since minimal concentrations of RANTES required for
activation of CCR5 on T cells are between 1 and 10 nM [28], about
threefold lower levels found in BAL derived from HIV-infected
patient (2700 pg/mL; ∼0.35 nM) are unlikely able to modulate
the receptor status, but indicate to a higher status of cell activation
in the lungs of HIV-1-infected persons.
RANTES levels directly correlated with viral load in BAL. On
restimulation of BAL cells with M. tuberculosis no upregulation
of the RANTES gene expression was observed. This suggests that
CCR5 agonist levels in BALMCs are influenced rather by HIV-1 sta-
tus than by M. tuberculosis infection. Regulation of β-chemokine
expression in BAL cells may differ from peripheral blood cells,
as the latter showed higher β-chemokine levels in active tubercu-
losis, compared with healthy controls [29] and peripheral levels
remained elevated in HIV-1 andM. tuberculosis coinfected persons
despite anti-tuberculosis treatment [30].
HIV-1 viral replication in the lungs may drive the produc-
tion of MIP-1β and RANTES. We speculate that this, at least in
part, reflects compartmentalised cytolytic activity of HIV-1-specific
CD8+ T cells [31, 32]. Circulating T cells that have been acti-
vated by β-chemokines and migrate to the site of infection, may
thus be preferentially infected by HIV-1 [33]. By contrast, locally
primed antigen-specific T cells are less permissive to HIV-1 infec-
tion, as CCR5 agonists compete with HIV-1 for binding sites of
the CCR5 receptor resulting in an inhibitory effect for HIV-1 entry
[14,30,33].
Our study had several limitations. Due to restricted numbers
of BAL cells we were unable to better characterise the CCR5+
T-cell populations in respect of memory or effector phenotyp-
ing and to investigate the HIV-1-specific immune response. Such
investigations would have allowed us to address whether, as
shown for peripheral blood cells, antigen-specific CD4+ BAL
T cells that express high levels of CCR5 are preferentially elim-
inated [34] or if ongoing viral replication would be a similar pre-
dictor of HIV-1-specific CD8+ T-cell loss in BAL [35]. Secondly,
it might be possible that HIV-1 infection preferentially depletes
M. tuberculosis-specific CCR5+ CD4+ T cells [9,23,36]. Although
we have not addressed this question specifically, data from
the same participants show that M. tuberculosis-specific T-cell
responses in lungs of HIV-1-infected persons are markedly
impaired [3]. It will be important to also study these effects of
HIV infection in patients with active pulmonary tuberculosis.
Conclusion
Elevated levels of CCR5, the coreceptor for HIV-1, on CD4+
BAL T cells in comparison to peripheral blood cells suggest a
local permissive environment for HIV-1 infection in human lungs.
HIV-1-infected persons also exhibited higher expression of CCR5
by CD8+ BAL T cells, suggesting that CCR5 may play an impor-
tant role in the recruitment of HIV-1-specific CD8+ effector T cells
into inflamed tissue where these CD8+ T cells may mediate killing
of HIV-infected cells. These results provide further evidence that
ongoing HIV-1 replication is an important factor in the elevation




The study was approved by the Research Ethics Committees of
the Universities of Cape Town, South Africa (REC 381/2006), and
Lu¨beck, Germany (05-096) and all participants provided written
informed consent. These investigations were performed as part of
a larger study. Cells from the same patient samples were used for
different experiments, these results focussing on the influence of
HIV-1 on M. tuberculosis-specific T-cell immune responses have
been previously published [3].
Briefly, participants were recruited at the Khayelitsha Site B
Clinic in Cape Town, South Africa. In compliance with South
African national guidelines HIV-1 care including ART was offered
to all HIV-1-infected persons. A symptom screen and physical
examination were performed, persons with active or a past history
of tuberculosis, or isoniazid preventive therapy were excluded.
Smoking, pregnancy, chronic cardiovascular or metabolic
illnesses, immunosuppressive medication, and age less than
21 years also constituted exclusions. All participants had
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Figure 4. Chemokine concentration of RANTES, MIP-1β and MIP-1α in serum and BAL of HIV-1-infected (n = 15, open squares) or HIV-1-uninfected
(n = 20, solid circles) persons. Chemokine concentrationwasmeasured bymultiplex bead array; each symbol represents one sample, bars represent
medians. (A) Differences of RANTES concentration between paired serum and BAL samples of HIV-1-infected (***p < 0.001) and HIV-1-uninfected
persons were assessed by Wilcoxon signed rank test. The RANTES level in BAL in HIV-1-infected in comparison with HIV-1-uninfected (***p <
0.001) was calculated by Mann–Whitney U-test. (B) Difference of MIP-1β concentration between paired serum and BAL samples of HIV-1-infected
participants (***p < 0.001) was assesses by Wilcoxon signed rank test. MIP-1β level in BAL was higher in HIV-1-infected versus HIV-1-uninfected
persons (**p = 0.004, Mann–Whitney U-test). (C) Wilcoxon signed rank test was used to compare MIP-1α level in paired blood and BAL samples
(***p < 0.001 in HIV-1-infected, **p = 0.01 in HIV-1-uninfected persons). (D) Correlation between RANTES concentration in BAL and viral load (VL)
in BAL were assessed by Spearman (ρ = 0.635, p = 0.011). Open circles, BAL VL; symbol ×, BAL VL LDL were set to a value of 19 copies/mL and
normalised according to the urea method. Data shown are pooled data from experiments on 15 HIV-1-infected and 20 HIV-1-uninfected persons.
negative cultures for M. tuberculosis in BAL and had no radio-
logical evidence of lung disease.
BAL and blood collection and processing
Bronchoscopy and blood collection were performed before
patients were initiated on ART. Standard flexible diagnostic bron-
choscopy including a BAL of the middle lobe with 300 mL ster-
ile saline and isolation of the bronchoalveolar mononuclear cells
(BALMCs) were conducted as described previously [3, 37]. BAL
fluid was harvested and aliquots were frozen immediately at
−80◦C. PBMCs were prepared as described previously [3, 37].
Serum samples were centrifugated at 3000 rpm for 15 min at
20◦C, aliquoted and frozen at −80◦C.
Latent M. tuberculosis infection
Sensitisation by M. tuberculosis was defined by the immune
responses to the M. tuberculosis-specific antigens early secreted
antigenic target (ESAT)-6 and culture filtrate protein (CFP)-10
measured in PBMCs by IFN-γ ELISPOT assay, MABTECH (Nacka,
Sweden) as reported previously [3].
HIV-1 viral load
Plasma HIV-1 viral load was detected by Nuclisens (BioMerieux,
Randburg, South Africa). Viral load in BAL fluid was measured by
Cobas TaqMan HIV-1 test (Roche Diagnostics GmbH, Grenzach-
Wyhlen, Germany). Both assays are accredited in vitro nucleic acid
amplification tests of gag for the quantitation of human HIV-1
RNA and both determine the results in copies/mL. The limit of
agreement between the two assays is reported to be 0.126 copies/
mL [38]. The detection limit was 20 copies/800 μL pure BAL
fluid. For analysis, values below the detection limit were assigned
19 copies/800μL BAL fluid. These values are specifically marked
in the figures. To allow direct comparison between viral load in
serum and BAL fluid, the dilution factor of the BAL procedure was
assesed by the urea method [39]. Urea was measured by BUN Flex
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Figure 5. Fold induction of CCR5 ligands in bronchoalveolar lavage
cells after 24 h M. tuberculosis stimulation. 5 × 105 BALMCs of
HIV-1-infected (n = 12, open squares) and HIV-1-uninfected partici-
pants (n = 8, solid circles) were cultured for 24 h in the presence or
absence of M. tuberculosis H37Rv at MOI 1:1. Fold induction was cal-
culated as (CT in the presence of H37Rv) − (CT in the absence of
H37Rv), values normalised by power 2× transformation. Each symbol
is representative of one sample, bars represent medians. Differences
between RANTES constitutive transcript abundance of HIV-1-infected
and -uninfected persons (*p = 0.034) were assessed by Mann–Whitney
test. Data shown are pooled data from experiments on 12 HIV-1-
infected and 8 HIV-1-uninfected persons.
reagent cartridge (DF21, Siemens Healthcare Diagnostics GmbH,
Eschborn, Germany). All data refer to copies/mL alveolar lining
fluid, for easier reading the term copies/mL BAL will be used
throughout the text.
Flow cytometry
For phenotypic analysis freshly isolated PBMCs and BALMCs
were stained with the surface marker antibodies (BD Biosciences,
Johannesburg, South Africa) anti-CD3 Pacific Blue (UCTH1), anti-
CD4 Alexa Fluor 700 (RPA-T4), anti-CD8 PerCP-Cy5.5 (SK1),
anti-CD184 allophycocyanin (12G5/CXCR4) and anti-CD195 PE
(2D7/CCR5). Staining and acquisition was performed as previ-
ously described [3]. The flow cytometric gating strategy is illus-
trated in the Supporting Information Fig. 1. Photomultiplier volt-
age settings were not changed in between group comparison.
Data analysis was performed with FlowJo software version 9.2
(TreeStar, Ashland, TX, USA).
mRNA analysis
To estimate constitutive transcript abundance RNA samples were
extracted immediately after BALMCs isolation. To compare the
differences in transcript abundance threshold cycle (CT) values
for β-actin were subtracted from the CT values of the gene of
interest. To analyse M. tuberculosis induced changes in transcript
levels, 5 × 105 BALMC were cultured for 24 h in a 24-well plate
with 1 mL RPMI and 10% heat-inactivated fetal calf serum (Gibco,
Mowbray, South Africa) in the presence or absence of M. tubercu-
losis H37Rv at MOI 1:1. RNA isolation and quantitative RT-PCR
were performed as previously described [40]. The fold induc-
tion of genes was calculated by the CT method (CT in the
presence of H37Rv minus CT in the absence of H37Rv in cul-
ture) and values normalised by power 2x transformation. RANTES,
MIP-1α and MIP-1β primers and probes were obtained from
Applied Biosystems (Foster City, CA, USA).
Multiplex bead array
MIP-1α, MIP-1β, RANTES and SDF-1α levels in serum and BAL
fluid were assayed in batches by multiplex bead array (Bio-
Rad Laboratories, Munich, Germany). Serum testing was per-
formed according to the manufacturer’s instructions (User Bulletin
#10014905 Rev C, download from http://bio-rad.com/bioplex).
500 μL BAL fluid was incubated with multiplex beads, 1% bovine
serum albumin (Sigma-Aldrich, Steinheim, Germany) and pro-
tease inhibitor (Roche, Mannheim, Germany) on a roller device at
4◦C overnight. BAL fluid volume was subsequently reduced on the
96-well Biorad plate with vacuum manifold. Samples were read
on the Biorad Luminex reader using Bioplex manager 4.1 soft-
ware. Chemokine levels in BAL fluid were normalised by the urea
method as pg/mL alveolar lining fluid, which for easier reading is
reported as pg/mL BAL throughout the manuscipt.
Data analysis
Due to relatively small cell numbers in individual samples, not
all analyses could be performed on all subjects. Statistical tests
between groups were performed by the Mann–Whitney U-test,
for paired data with the Wilcoxon Signed Rank test and for
2 × 2 tables Fisher’s exact test of probability. Non-parametric
correlation was assessed by Spearman coefficient, association
between normally distributed data was tested by Pearson’s cor-
relation test. Comparison in figures are indicated as *p < 0.05;
**p < 0.005 and ***p < 0.0005.
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